STOCK TITAN

Tscan Therapeutics Inc - TCRX STOCK NEWS

Welcome to our dedicated news page for Tscan Therapeutics (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tscan Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tscan Therapeutics's position in the market.

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) reports updated data from Phase 1 study showing positive outcomes for heme malignancies treatment. They also announced the clearance of two additional INDs for their Solid Tumor Program. Financially, the company has strong cash reserves to fund operations into 2026 and has seen revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings
-
Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference. The event will be held on March 6, 2024, at 9:10 a.m. Eastern Time in Boston. A webcast of the panel discussion will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences
-
Rhea-AI Summary
TScan Therapeutics, Inc. presents positive data at the 2024 Tandem Meetings, showing high success rates in preventing relapse in patients with AML, MDS, and ALL using TSC-100 and TSC-101. All treated patients achieved complete donor chimerism, with no relapses to date. The company will host a virtual KOL event to discuss the data further.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
clinical trial
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will host a virtual KOL event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings. The event will focus on TSC-100 and TSC-101 in treating residual disease and preventing relapse in patients with AML, MDS, or ALL. The Company will also discuss initial data from a clinical trial on donor chimerism and relapse risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences clinical trial
-
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings over a decade of experience in clinical development across the pharmaceutical and biotechnology industry. TScan remains on track to dose the first patient in the Phase 1 solid tumor study in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
management clinical trial
-
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints Jason A. Amello as Chief Financial Officer, bringing nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry. The company is making significant progress across both heme and solid tumor programs, with recent positive initial data from its Phase 1 heme program, INDs clearance for the use of multiple TCRs in solid tumor clinical trials, and a strong balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
management
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, designed to treat residual disease and prevent relapse following hematopoietic cell transplantation in patients with AML, MDS, or ALL. The abstract was selected to receive a Best Abstracts Award, and the presentation details include the title, authors, abstract ID number, session, date & time, and location. A copy of the presentation materials will be added to the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
none
-
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting, cleared INDs for four TCR-Ts, entered a collaboration with Amgen, and closed an underwritten public offering with net proceeds of $140.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced promising initial data from a Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL). Six treatment-arm patients achieved complete donor chimerism and MRD negativity, indicating no relapses, while one of four control-arm patients relapsed at six months. The company also announced plans to host a virtual KOL event to discuss the data presented at the ASH Annual Meeting and Exposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints R. Keith Woods, a highly experienced leader in the biopharmaceutical sector, to its Board of Directors. With over 30 years of life science experience, Mr. Woods brings expertise in commercialization, sales, global operations, and business strategy. His appointment is expected to support the growth of TScan and advance its compelling pipeline of T cell receptor (TCR)-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
management
Tscan Therapeutics Inc

Nasdaq:TCRX

TCRX Rankings

TCRX Stock Data

397.42M
21.10M
0.89%
83.13%
0.39%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Waltham

About TCRX

harnessing novel t cell systems to extend the promise of immunotherapy